Executive interview: Volition – Q222 earnings

Volition is a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis (NETs), such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring [in humans,?] but also has a subsidiary focused on animal diagnostics and monitoring.

In this video, Cameron Reynolds, Volition’s chief executive officer, discusses the company’s Q222 financial and operating results. During the quarter, the team secured a CE Mark for Nu.Q NETs in Europe and announced new clinical studies for NETs in the US, with both MD Anderson and Diagnostic Oncology CRO. On the veterinary side, Volition continues to work with Heska Corporation on supplying the Nu.Q Vet Cancer Screening Test globally and continues to make good progress with other potential licensing and supply partners.